Recent Pfizer Press Releases

  • 10/25/07 4:45 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer said today that after a 31-year career Vice Chairman David L. Shedlarz will retire from the company at the end of this year. Mr. Shedlarz’s contributions to the company include helping to shape the strategic direction that drove Pfizer’s growth to pharmaceutical industry leadership; fifteen years of service on Pfizer’s senior management committee and ten as its Chief Financial Officer; andmore...
  • 10/25/07 1:00 pm EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent fourth-quarter, 2007, dividend on the company's common stock, payable December 4, 2007, to shareholders of record at the close of business on November 9, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The fourth-quartermore...
  • 10/23/07 9:51 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010. The patent was challenged by generic manufacturer Lek Pharmaceuticals D.D., and is one of four separate challenges to the calcium salt patent by genericmore...
  • 10/18/07 6:30 am EDT
    • Third-Quarter 2007 Reported Diluted EPS of $0.11 Represents a Decline of 76% Compared to the Same Period Last Year and Includes Charges of $0.31 ($2.8 Billion Pre-Tax) Related to a Decision to Exit Exubera
    • Adjusted Diluted EPS(1) of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago
    • New Products(3) Posted Significant Growth in Revenues; Overall Third-Quarter 2007 Revenues were Adversely Impacted by Loss of U.S. Exclusivity for Norvasc and Zoloft
    • Worldwide Lipitor Revenues were $3.2 Billion in the Third Quarter of 2007 Compared to $3.3 Billion in the Third Quarter of 2006
    NEW YORK--(BUSINESS WIRE)--Pfizer: ($ in millions, except per-share amounts)     Third Quarter   Year to Date   2007   2006more...
  • 10/15/07 12:01 am EDT

    Company Aims To Open Information Exchange with Doctors through Unique Online Collaboration

    NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc (www.pfizer.com) and Sermo (www.sermo.com), the nation’s largest online physician community, today announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide newmore...
  • 10/11/07 11:00 am EDT

    Brookings Institution, Pfizer and FSG Social Impact Advisors Release Findings from Independent Analysis of International Corporate Volunteering Programs

    WASHINGTON--(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc, today released a landmark independent report researched and written by FSG on the state of international corporate volunteering (ICV) programs. The report details the landscape of this emerging trend among multinationals, the perceived business value of ICV and community impact, and the businessmore...
  • 10/5/07 11:06 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Thursday, October 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2007 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visitmore...
  • 10/4/07 9:00 am EDT

    Pfizer Launches Independent Biotherapeutics and Bioinnovation Center, Headed by Dr. Corey Goodman

    Dr. Briggs Morrison Named Head of Clinical Development

    NEW YORK--(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Dr. Corey Goodman; and named Dr. Briggs Morrison, who held senior research and development positions at Merck, as its new Head of Clinical Development for the PGRD pipeline. “As themore...
  • 10/3/07 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join Pfizer as vice president and Chief Talent Officer in November. Dr. Clemons will report to Mary McLeod, the senior vice president for Worldwide Talent Development and Human Resources. She will be a member of the Human Resources Leadership Team and Pfizermore...
  • 9/28/07 12:32 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra would be infringed by Apotex’ proposed generic product. The court granted the company’s application for an order preventing Apotex from launching a generic version of Viagra until expiration of Canadian Patent No. 2,163,446 in 2014. The decision is subject tomore...